A new article by AHRQ researchers estimates that adverse drug events (ADEs) associated with anticoagulants and hypoglycemic agents each added about $2.5 billion to annual hospital costs in 2013. Adverse events are common among hospital patients who are treated with anticoagulants to encourage blood clotting or hypoglycemic agents to manage blood sugar levels. Researchers used nationally representative hospital data from the agency’s Healthcare Cost and Utilization Project and the Medicare Patient Safety Monitoring System to identify adverse events and calculate associated additional hospital costs. They estimated that in 2013 there were 250,000 ADEs from anticoagulants and 600,000 ADEs from hypoglycemic agents. Anticoagulant ADEs added more to the cost of hospital stays than hypoglycemic ADEs ($10,250 versus $4,300). Access the abstract of the article, which was published in the journal Medical Care.
Med Care. 2017 Jul 24. doi: 10.1097/MLR.0000000000000780. [Epub ahead of print]
The Marginal Costs of Adverse Drug Events Associated With Exposures to Anticoagulants and Hypoglycemic Agents During Hospitalization.
RESEARCH DESIGN AND SUBJECT: